Last updated on December 2016

Phase 3 Study of KHK7580


Brief description of study

This long-term study is designed to evaluate safety and efficacy of KHK7580 orally administered once daily for 52 weeks for patients with secondary hyperparathyroidism receiving hemodialysis.

Clinical Study Identifier: NCT02549404

Contact Investigators or Research Sites near you

Start Over

Kyowa Hakko Kirin

For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin
Tokyo, Japan
  Connect »